Science & Enterprise subscription

Follow us on Twitter

  • Growth patterns in the U.S. show a concentration of technology development in a few cities, with new policies and i… https://t.co/MhS25iyLfB
    about 1 day ago
  • Many thanks @SciSeeker ... much appreciated https://t.co/IW2mhV5F8E
    about 1 day ago
  • New post on Science and Enterprise: Report – U.S. Needs Regional Technology Centers https://t.co/rn5v6k5qdJ #Science #Business
    about 1 day ago
  • The World Solved the Ozone Problem. It Can Solve Climate Change. https://t.co/BVlMgafyiM
    about 2 days ago
  • A solid majority of Americans now says that climate change affects their communities, a finding that could affect f… https://t.co/FeSjrqpv7t
    about 3 days ago

Please share Science & Enterprise

Recap – Editas Medicine Advances Crispr Therapy

Crispr genome edits illustration

(NIH.gov)

2 Dec. 2018. While much the world watched, and disapproved of, a Chinese researcher editing the genomes of embryos leading to the birth of twins, Editas Medicine in Cambridge, Massachusetts received the go-ahead to conduct a clinical trial using the genome editing technique Crispr. On Friday, the Food and Drug Administration, in an approved investigational new drug application, authorized Editas to test Crispr as a treatment for a rare inherited eye disease known as Leber congenital amaurosis type 10.

Here’s what else we reported on last week:

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.